SeaCrest Wealth Management LLC Takes Position in Illumina, Inc. (ILMN)

SeaCrest Wealth Management LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 707 shares of the life sciences company’s stock, valued at approximately $154,000.

A number of other institutional investors have also added to or reduced their stakes in ILMN. Dimensional Fund Advisors LP lifted its position in Illumina by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 266,817 shares of the life sciences company’s stock valued at $46,304,000 after purchasing an additional 1,892 shares during the period. Raymond James Financial Services Advisors Inc. lifted its position in Illumina by 2.1% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 5,698 shares of the life sciences company’s stock valued at $989,000 after purchasing an additional 116 shares during the period. Castleark Management LLC acquired a new position in Illumina during the 2nd quarter valued at about $392,000. Advisory Services Network LLC lifted its position in Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 89 shares during the period. Finally, Toronto Dominion Bank lifted its position in Illumina by 25.3% during the 2nd quarter. Toronto Dominion Bank now owns 49,462 shares of the life sciences company’s stock valued at $8,581,000 after purchasing an additional 9,976 shares during the period. Institutional investors own 92.04% of the company’s stock.

A number of analysts recently weighed in on ILMN shares. Wells Fargo & Co upgraded shares of Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price target on the stock in a research report on Tuesday, January 2nd. Morgan Stanley increased their price target on shares of Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a research report on Thursday, December 14th. Citigroup increased their price target on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $252.00 price target on the stock in a research report on Tuesday, December 5th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $269.00 price target on shares of Illumina in a research report on Tuesday, January 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $241.39.

In other news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $211.35, for a total transaction of $4,227,000.00. Following the completion of the transaction, the director now directly owns 531,717 shares of the company’s stock, valued at approximately $112,378,387.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $216.87, for a total transaction of $433,740.00. Following the transaction, the executive vice president now directly owns 27,952 shares of the company’s stock, valued at $6,061,950.24. The disclosure for this sale can be found here. Insiders have sold a total of 114,440 shares of company stock worth $25,318,904 over the last 90 days. Corporate insiders own 0.89% of the company’s stock.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $223.11 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.55 and a current ratio of 3.99. The company has a market cap of $32,570.00, a P/E ratio of 45.26, a price-to-earnings-growth ratio of 2.92 and a beta of 0.92. Illumina, Inc. has a fifty-two week low of $158.02 and a fifty-two week high of $248.97.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.22 by $0.22. The firm had revenue of $778.00 million for the quarter, compared to the consensus estimate of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The business’s quarterly revenue was up 25.7% on a year-over-year basis. During the same period last year, the company posted $0.85 EPS. equities analysts anticipate that Illumina, Inc. will post 4.59 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “SeaCrest Wealth Management LLC Takes Position in Illumina, Inc. (ILMN)” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/15/seacrest-wealth-management-llc-takes-position-in-illumina-inc-ilmn.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply